Alexion Pharmaceuticals, Inc. logo
Alexion Pharmaceuticals, Inc. ALXN

Alexion Pharmaceuticals, Inc. Financial Statements 2011-2026 | ALXN

Annual Financial Statements Alexion Pharmaceuticals, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

33.6 B 22.4 B 27 B 27.4 B 28.7 B 31.1 B 36.3 B 31.7 B 18.2 B 13.7 B

Shares

219 M 223 M 223 M 224 M 224 M 213 M 198 M 196 M 190 M 183 M

Net Income

603 M 2.4 B 77.6 M 443 M 399 M 144 M 657 M 253 M 255 M 175 M

Revenue

6.07 B 4.99 B 4.13 B 3.55 B 3.08 B 2.6 B 2.23 B 1.55 B 1.13 B 783 M

EBITDA

3.11 B 2.45 B 1.91 B 1.12 B 1.12 B 799 M 963 M 567 M 454 M 245 M

Operating Expenses

2.66 B 2.46 B 2.16 B 2.29 B 2.03 B 1.69 B 1.14 B 807 M 608 M 446 M

General and Administrative Expenses

1.4 B 1.26 B 1.11 B 1.09 B 954 M 863 M 630 M 490 M 385 M 308 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Alexion Pharmaceuticals, Inc. ALXN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Alexion Pharmaceuticals, Inc. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.22 -2.32 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.82 -3.48 % $ 4.47 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 164.71 -1.01 % $ 8.19 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.73 -2.49 % $ 1.11 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 8.5 -2.63 % $ 1.39 B britainBritain
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.88 - $ 2.92 B usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 18.08 1.06 % $ 868 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Certara Certara
CERT
$ 7.19 1.93 % $ 1.15 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 17.72 -2.37 % $ 454 M usaUSA
Exelixis Exelixis
EXEL
$ 40.99 -0.1 % $ 11.1 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Galapagos NV Galapagos NV
GLPG
$ 33.13 -2.82 % $ 2.69 B belgiumBelgium
Greenwich LifeSciences Greenwich LifeSciences
GLSI
$ 27.7 1.12 % $ 361 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 27.67 -6.69 % $ 17.7 B danmarkDanmark
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 26.04 -3.07 % $ 697 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
$ 0.99 -2.92 % $ 72.7 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 69.39 -0.67 % $ 8.32 B usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 28.56 -1.19 % $ 1.64 B usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 6.3 -3.67 % $ 51.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.75 -0.69 % $ 6.43 M australiaAustralia
Immatics N.V. Immatics N.V.
IMTX
$ 9.86 -1.3 % $ 620 M germanyGermany
Immunic Immunic
IMUX
$ 1.1 3.3 % $ 171 M usaUSA
Immunovant Immunovant
IMVT
$ 26.99 -2.74 % $ 4.09 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Inhibrx Inhibrx
INBX
$ 75.96 -1.97 % $ 3.58 B usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 0.75 -8.49 % $ 1.84 M canadaCanada
INmune Bio INmune Bio
INMB
$ 1.41 6.07 % $ 25.4 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 146.89 0.39 % $ 29.2 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
$ 3.19 -4.49 % $ 1.14 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.63 -1.21 % $ 235 M franceFrance
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 29.11 -0.31 % $ 1.69 B usaUSA